Results 91 to 100 of about 47,935 (263)

Patients and blood donors with hemochromatosis: A survey conducted in Førde Health Trust

open access: yesBioingeniøren, 2021
Introduction: To allow eligible persons with hemochromatosis to become blood donors will be advantageous for these individuals and for the blood supply.
Turid Aarhus Braseth   +2 more
doaj  

EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH)

open access: yesEuropean Journal of Human Genetics, 2015
Molecular genetic testing for hereditary hemochromatosis (HH) is recognized as a reference test to confirm the diagnosis of suspected HH or to predict its risk.
G. Porto   +8 more
semanticscholar   +1 more source

Prevalence and risk factors for metabolic dysfunction–associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort

open access: yesJournal of Internal Medicine, EarlyView.
Abstract Background and Aims Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, but its prevalence and severity remain poorly characterized in the general population. Our aim was to estimate the prevalence of MASLD and the risk of advanced fibrosis in a large Swedish general population ...
Oumarou Nabi   +10 more
wiley   +1 more source

Should the Children of Patients with Hemochromatosis be Screened for the Disease?

open access: yesCanadian Journal of Gastroenterology, 1988
Idiopathic hemochromatosis is an underdiagnosed treatable condition inherited in an autosomal recessive pattern. Since early treatment is of demonstrated value, screening of high risk groups of individuals in a valuable exercise in preventive medicine ...
Donald G. MacIntosh   +5 more
doaj   +1 more source

Multinational transfusion practices and outcomes in haematology patients admitted to the intensive care unit

open access: yesVox Sanguinis, EarlyView.
Abstract Background and Objectives The number of critically ill patients with haematological conditions is increasing, yet transfusion practices in this population remain poorly defined. This study aimed to compare transfusion strategies in critically ill patients with versus without haematological conditions.
Caroline M. Schaap   +288 more
wiley   +1 more source

Eligibility and Exclusion of Hemochromatosis Patients as Voluntary Blood Donors

open access: yesCanadian Journal of Gastroenterology, 1998
BACKGROUND: Hereditary hemochromatosis patients are excluded in many countries as voluntary blood donors. In 1991, changes in the Canadian Red Cross policy allowed healthy hemochromatosis patients to become voluntary donors.
M Levstik, PC Adams
doaj   +1 more source

Genetic Information and the Workplace - Full Report [PDF]

open access: yes, 1998
Joint Agency ReportGeneticInfoWorkplace1998.pdf: 800 downloads, before Oct.
Department of Health and Human Services, U.S.   +2 more
core   +1 more source

Genetic variants underlying precancerous conditions of hepatocellular carcinoma

open access: yesInternational Journal of Cancer, Volume 158, Issue 3, Page 488-502, 1 February 2026.
Abstract Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 80% of cases worldwide. While chronic hepatitis B and C infections remain primary risk factors, emerging evidence highlights the increasing contributions of metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated liver disease
Jonathan Jaime G. Guerrero   +7 more
wiley   +1 more source

Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

open access: yesHepatology, 2011
This guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and represents the position of the association.
B. Bacon   +4 more
semanticscholar   +1 more source

Mitochondrial Transporter ABCB10 Protects Against Doxorubicin‐Induced Respiratory Muscle Dysfunction Independent of Changes to Diaphragm Accumulation

open access: yesJournal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT Background Doxorubicin (DOX) is a highly effective chemotherapeutic agent whose use can cause respiratory toxicity, increasing patient fatigue and negatively impacting quality of life and survival. These adverse effects occur due to diaphragm muscle mitochondrial accumulation of DOX, where it causes reactive oxygen species production and iron ...
Ashley J. Smuder   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy